You just read:

Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma

News provided by

Amgen

Jul 12, 2017, 16:00 ET